Comparison of inhaled corticosteroids

Annals of Pharmacotherapy

Volumn 32, Issue 2, 1998, Pages 220-232

  Kelly, H William ^a  

^a UNIVERSITY OF NEW MEXICO   (United States)

Author keywords

Asthma; Beclomethasone dipropionate; Budesonide; Corticosteroids; Flunisolide; Fluticasone; Metered dose inhaler; Triamcinolone acetonide

Indexed keywords

BECLOMETASONE DIPROPIONATE; BUDESONIDE; CORTICOSTEROID; FLUNISOLIDE; FLUTICASONE; FLUTICASONE PROPIONATE; TRIAMCINOLONE ACETONIDE;

ASTHMA; DEVICE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; HUMAN; INHALATIONAL DRUG ADMINISTRATION; METERED DOSE INHALER; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW;

ADMINISTRATION, INHALATION; ADMINISTRATION, TOPICAL; ADOLESCENT; ADULT; AGED; ANTI-INFLAMMATORY AGENTS; ASTHMA; BRONCHODILATOR AGENTS; CHILD; CLINICAL TRIALS; FEMALE; GLUCOCORTICOIDS; HUMANS; MALE; MIDDLE AGED; NEBULIZERS AND VAPORIZERS; RESPIRATORY FUNCTION TESTS; STEROIDS;

EID: 0031895196     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.17014     Document Type: Review

References (106)

1. NHLBI, National Asthma Education Program, Expert Panel Report. Guidelines for the diagnosis and management of asthma. Publication no. 91-3042. Bethesda, MD: US Department of Health and Human Services, 1991.
2. Global Initiative for Asthma. Global strategy for asthma management and prevention NHLBI/WHO workshop report. National Institutes of Health, National Heart, Lung and Blood Institute publication no. 95-3659. Bethesda, MD: 1995.
3. Barnes PJ, Pedersen S. Efficacy and safety of inhaled corticosteroids in asthma. Am Rev Respir Dis 1993;148(suppl):S1-26.
4. Barnes PJ. Inhaled glucocorticoids for asthma. N Engl J Med 1995; 332:868-75.
5. Baraniuk JN, ed. Steroids in asthma: molecular mechanisms of glucocorticoid actions. J Allergy Clin Immunol 1996;97(suppl):141-82.
6. Kamada A, Szefler SJ, Martin RJ, Boushey HA, Chinchilli VM, Drazen JM, et al. Issues in the use of inhaled glucocorticoids. Am J Respir Crit Care Med 1996;153:1739-48.
7. Lipworth BJ. Airway and systemic effects of inhaled corticosteroids in asthma: dose response relationship. Pulm Pharmacol 1996;9:19-27.
8. Brattsand R, Thalen A, Roempke K, Kallstrom L, Gruvstad E. Development of new glucocorticoids with a very high ratio between topical and systemic activities. Eur J Respir Dis 1982;63(suppl 122):62-73.
9. McKenzie AW, Stoughton RB. Method for comparing percutaneous absorption of steroids. Arch Dermatol 1962;86:611-4.
10. Phillipps GH. Structure-activity relationships of topically active steroids: the selection of fluticasone propionate. Respir Med 1990;84(suppl A):19-23.
11. Johansson S-A, Andersson K-E, Brattsand R, Gruvstad E, Hedner P. Topical and systemic glucocorticoid potencies of budesonide, beclomethasone dipropionate and prednisolone in man. Eur J Respir Dis 1982;63(suppl 122):74-81.
12. English AF, Neate MS, Quint DJ, Sareen M. Biological activities of some corticosteroids used in asthma (abstract). Am J Respir Crit Care Med 1994;149(suppl):A212.
13. Harris DM. Some properties of beclomethasone dipropionate and related steroids in man. Postgrad Med J 1975;51(suppl 4):20-5.
14. Check WA, Kaliner MA. Pharmacology and pharmacokinetics of topical corticosteroid derivatives used for asthma therapy. Am Rev Respir Dis 1990;141(suppl):S44-51.
15. Derendorf H, Hochhaus G, Mollmann H, Barth J, Krieg M, Turin S, et al. Receptor-based pharmacokinetic-pharmacodynamic analysis of corticosteroids. J Pharmacol 1993;33:115-23.
16. Dahlberg E, Thalen A, Brattsand R, Gustafsson J-A, Johansson U, Roempke K, et al. Correlation between chemical structure, receptor binding, and biological activity of some novel, highly active, 16α,17α-acetal-substituted glucocorticoids. Mol Pharmacol 1984;25:70-8.
17. Jusko WJ. Corticosteroid pharmacodynamics: models for a broad array of receptor-mediated pharmacologic effects. J Clin Pharmacol 1990;30: 303-10.
18. Lee TH, Brattsand R, Leung D, eds. Corticosteroid action and resistance in asthma. Am J Respir Crit Care Med 1996;154(suppl):S1-79.
19. Szefler SJ. Glucocorticoid therapy for asthma: clinical pharmacology. J Allergy Clin Immunol 1991;88:147-65.
20. Davies B. A comparison of beclomethasone dipropionate and budesonide in the treatment of asthma. Br J Clin Pract 1993;47:87-93.
21. Chaplin MD, Rooks W II, Swenson EW, Cooper WC, Nerenberg C, Chu NI. Flunisolide metabolism and dynamics of a metabolite. Clin Pharmacol Ther 1980;27:402-13.
22. Pedersen S, Steffensen G, Ohlsson SV. The influence of orally deposited budesonide on the systemic availability of budesonide after inhalation from a Turbuhaler. Br J Clin Pharmacol 1993;36:211-4.
23. 14C triamcinolone acetonide administrated as single oral dose of 100 μci (800 μg) to healthy volunteers. Presented at Asthma Theory to Treatment, Chicago, IL, July 15-17, 1995. Data on file. Rhône-Poulenc Rorer.
24. Harding SM. The human pharmacology of fluticasone propionate. Respir Med 1990;84(suppl A):25-9.
25. Clissold SP, Heel RC. Budesonide: a preliminary review of its pharmacodynamic properties and therapeutic efficacy in asthma and rhinitis. Drugs 1984;28:485-518.
26. Mollman H, Rohdewald P, Schmidt EW, Salomon V, Derendorf H. Pharmacokinetics of triamcinolone acetonide and its phosphate ester. Eur J Clin Pharmacol 1985;29:85-9.
27. Martin LE, Tanner RJN, Clark THJ, Cochrane GM. Absorption and metabolism of orally administered beclomethasone dipropionate. Clin Pharmacol Ther 1974;15:267-75.
28. Wurthwein G, Rohdewald P. Activation of beclomethasone dipropionate by hydrolysis to beclomethasone-17-monopropionate. Biopharm Drug Disp 1990;11:381-94.
29. Rohdewald P, Rehder S. Plasma levels of beclomethasone dipropionate (BDP) and its 17-monopropionate metabolite (17-BMP) following BDP inhalation (abstract). Eur Respir J 1994;7(suppl 18):382S.
30. Thorsson L, Edsbacker S, Conradson T-B. Lung deposition of budesonide from Turbuhaler is twice that from a pressurized metered-dose inhaler P-MDI. Eur Respir J 1994;7:1839-44.
31. Chaplin MD, Cooper WC, Segre EJ, Oren J, Jones RE, Nerenberg C. Correlation of flunisolide plasma levels to eosinopenic response in humans. J Allergy Clin Immunol 1980;65:445-53.
32. Thorsson L, Kallen A, Wiren JE, Paulson J. Pharmacokinetics of inhaled fluticasone propionate (abstract). Am J Respir Crit Care Med 1996;153 (suppl):A801.
33. Hogger P, Bonsmann U, Rohdewald P. Efflux of glucocorticoids from human lung tissue to human plasma in vitro (abstract). Eur Respir J 1994;7(suppl 18):382S.
34. Lipworth BJ. New perspectives on inhaled drug delivery and systemic bioactivity. Thorax 1995;50:105-10.
35. Kim CS, Eldridge MA, Sackner MA. Oropharyngeal deposition and delivery aspects of metered-dose inhaler aerosols. Am Rev Respir Dis 1987;135:157-64.
36. Ahrens R, Lux C, Bahl T, Han S-H. Choosing the metered-dose inhaler spacer or holding chamber that matches the patient's need: evidence that the specific drug being delivered is an important consideration. J Allergy Clin Immunol 1995;96:288-94.
37. Barry PW, O'Callaghan C. Inhalational drug delivery from seven different spacer devices. Thorax 1996;51:835-40.
38. Miller MR, Bright P. Differences in output from corticosteroid inhalers used with a volumatic spacer. Eur Respir J 1995;8:1637-8.
39. Package insert. Flovent (fluticasone propionate). Research Triangle Park: Glaxo Wellcome, 1996.
40. Pizzichini MMM, Popov TA, Efthimiadis A, Hussack P, Evans S, Pizzichini E, et al. Spontaneous and induced sputum to measure indices of airway inflammation in asthma. Am J Respir Crit Care Med 1996;154: 866-9.
41. Gauvreau GM, Doctor J, Watson RM, Jordana M, O'Byrne PM. Effects of inhaled budesonide on allergen-induced airway responses and airway inflammation. Am J Respir Crit Care Med 1996;154:1267-71.
42. Barnes PJ, Kharitonov SA. Exhaled nitric oxide: a new lung function test. Thorax 1996;51:233-7.
43. Kharitonov SA, Yates DH, Chung KF, Barnes PJ. Changes in the dose of inhaled steroid affect exhaled nitric oxide levels in asthmatic patients. Eur Respir J 1996;9:196-201.
44. Geddes DM. Inhaled corticosteroids: benefits and risks. Thorax 1992;47: 404-7.
45. Boyd G. Effect of inhaled corticosteroids on bone. Respir Med 1994;88 (suppl A):45-52.
46. Wolthers OD. Long-, intermediate-and short-term growth studies in asthmatic children treated with inhaled glucocorticoids. Eur Respir J 1996;9:821-7.
47. 2-agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma. N Engl J Med 1991;325: 388-92.
48. Juniper EF, Kline PA, Vanzielghem MA, Ramsdale EH, O'Byrne PM, Hargreave FE. Effect of long-term treatment with an inhaled corticosteroid (budesonide) on airway hyperresponsiveness and clinical asthma in nonsteroid-dependent asthmatics. Am Rev Respir Dis 1990;142:832-6.
49. Bel EH, Timmers MC, Hermans J, Dijkman JH, Sterk PJ. The long-term effects of nedocromil sodium and beclomethasone dipropionate on bronchial responsiveness to methacholine in nonatopic asthmatic subjects. Am Rev Respir Dis 1990;141:21-8.
50. Kraan J, Koeter GH, van der Mark TW, Boorsma M, Kukler J, Sluiter HJ, et al. Dosage and time effects of inhaled budesonide on bronchial hyperreactivity. Am Rev Respir Dis 1988;137:44-8.
51. Toogood JH, Andreou P, Baskerville J. A methodological assessment of diurnal variability of peak flow as a basis for comparing different inhaled steroid formulations. J Allergy Clin Immunol 1996;98:555-62.
52. Kerstjens HA, Brand PLP, de Jong PM, Koeter GH, Postma DS. Influence of treatment on peak expiratory flow and its relation to airway hyperresponsiveness and symptoms. Thorax 1994;49:1109-15.
53. Pedersen S, Hansen OR. Budesonide treatment of moderate and severe asthma in children: a dose-response study. J Allergy Clin Immunol 1995;95:29-33.
54. Haahtela T, Jarvinen M, Kava T, Kiviranta K, Koskinen S, Lehtonen K, et al. Effects of reducing or discontinuing inhaled budesonide in patients with mild asthma. N Engl J Med 1994;331:700-5.
55. Waalkens HJ, van Essen-Zandvliet EE, Hughes MD, Gerritsen J, Duiverman EJ, Knol K, et al. Cessation of long-term treatment with inhaled corticosteroid (budesonide) in children with asthma results in deterioration. Am Rev Respir Dis 1993;148:1252-7.
56. Agertoft L, Pedersen S. Importance of the inhalation device on the effect of budesonide. Arch Dis Child 1993;69:130-3.
57. Lorentzson S, Boe J, Eriksson G, Persson G. Use of inhaled corticosteroids in patients with mild asthma. Thorax 1990;45:733-5.
58. Namsirikul P, Chaisupamongkollarp S, Chantadisai N, Bamberg P. Comparison of inhaled budesonide with oral prednisolone at two dose-levels commonly used for the treatment of moderate asthma. Eur Respir J 1989;2:317-24.
59. Toogood JH, Baskerville JC, Jennings B, Lefcoe NM, Johansson SA. Influence of dosing frequency and schedule on the response of chronic asthmatics to the aerosol steroid, budesonide. J Allergy Clin Immunol 1982;70:288-98.
60. Tarlo SM, Broder I, Davies GM, Leznoff A, Mintz S, Corey PN. Sixmonth double-blind, controlled trial of high dose, concentrated beclomethasone dipropionate in the treatment of severe asthma. Chest 1988; 93:998-1002.
61. Malo J-L, Cartier A, Merland N, Ghezzo H, Burek A, Morris J, et al. Four-times-a-day dosing frequency is better than twice-a-day regimen in subjects requiring a high-dose inhaled steroid, budesonide, to control moderate to severe asthma. Am Rev Respir Dis 1989;140:624-8.
62. Bjorkander J, Formgren H, Johansson SA, Millqvist E. Methodological aspects on clinical trials with inhaled corticosteroids: results of two comparisons between two steroid aerosols in patients with asthma. Eur J Respir Dis 1982;63(suppl 122):108-17.
63. Rosenhall L, Lundqvist G, Adelroth E, Glennow C. Comparison between inhaled and oral corticosteroids in patients with chronic asthma. Eur J Respir Dis 1982;63(suppl 122):154-62.
64. Stiksa G, Glennow C, Johannesson N. An open cross-over trial with budesonide and beclomethasone dipropionate in patients with bronchial asthma. Eur J Respir Dis 1982;63(suppl 122):266-7.
65. Field HV, Jenkinson PMA, Frame MH, Warner JO. Asthma treatment with a new corticosteroid aerosol, budesonide, administered twice daily by spacer. Arch Dis Child 1982;57:864-6.
66. Willey RF, Godden DJ, Carmichael J, Preston P, Frame M, Crompton GK. Comparison of twice daily administration of a new corticosteroid budesonide with beclomethasone dipropionate four times daily in the treatment of chronic asthma. Br J Dis Chest 1982;76:61-8.
67. Ebden P, Jenkins A, Houston G, Davies BH. Comparison of two high dose corticosteroid aerosol treatments, beclomethasone dipropionate (1500 μg/day) and budesonide (1600 μg/day), for chronic asthma. Thorax 1986;41:869-74.
68. Rafferty P, Tucker LG, Frame MH, Fergusson RJ, Biggs B-A, Crompton GK. Comparison of budesonide and beclomethasone dipropionate in patients with severe chronic asthma: assessment of relative prednisolonesparing effects. Br J Dis Chest 1985;79:244-50.
69. Baran D. A comparison of inhaled budesonide and beclomethasone dipropionate in childhood asthma. Br J Dis Chest 1987;81:170-5.
70. Springer C, Avital A, Maayan CH, Rosler A, Godfrey S. Comparison of budesonide and beclomethasone dipropionate for treatment of asthma. Arch Dis Child 1987;62:815-9.
71. Svendsen UG, Frolund L, Heinig JH, Madsen F, Nielsen NH, Weeke B. High-dose inhaled steroids in the management of asthma: a comparison of the effects of budesonide and beclomethasone dipropionate on pulmonary function, symptoms, bronchial responsiveness and the adrenal function. Allergy 1992;47:174-80.
72. Gustafsson P, Tsanakas J, Gold M, Primhak R, Radford R, Gillies E. Comparison of the efficacy and safety of inhaled fluticasone propionate 200 μg/day with inhaled beclomethasone dipropionate 400 μg/day in mild and moderate asthma. Arch Dis Child 1993;69:206-11.
73. Fabbri L, Burge PS, Croonenborgh L, Warlies F, Weeke B, Ciaccia A, et al. Comparison of fluticasone propionate with beclomethasone dipropionate in moderate to severe asthma treated for one year. Thorax 1993; 48:817-23.
74. Lundback B, Alexander M, Day J, Hebert J, Holzer R, Van Uffelen R, et al. Evaluation of fluticasone propionate (500 μg day-1) administered either as dry powder via Diskhaler inhaler or pressurized inhaler and compared with beclomethasone dipropionate (1000 μg day-1) administered by pressurized inhaler. Respir Med 1993;87:609-20.
75. Barnes NC, Marone G, Di Maria GU, Visser S, Utama I, Payne SL. A comparison of fluticasone propionate 1 mg daily with beclomethasone dipropionate 2 mg daily in the treatment of severe asthma. Eur Respir J 1993;6:877-84.
76. Dahl R, Lundback B, Malo J-L, Mazza JA, Nieminen MM, Saarelainen P, et al. A dose-ranging study of fluticasone propionate in adult patients with moderate asthma. Chest 1993;104:1352-8.
77. Leblanc P, Mink S, Keistinen T, Saarelainen PA, Ringdal N, Payne SL. A comparison of fluticasone propionate 200 μg/day with beclomethasone dipropionate 400 μg/day in adult asthma. Allergy 1994;49:380-5.
78. Boe J, Bakke P, Rodolen T, Skovlund E, Gulsvik A. High-dose inhaled steroids in asthmatics: moderate efficacy gain and suppression of the hypothalamic-pituitary-adrenal (HPA) axis. Eur Respir J 1994;7:2179-84.
79. Pauwels RA, Demedts MG, Yernault JC, Geusens P, Roosens WA. Comparison of long-term safety and efficacy of fluticasone propionate and beclomethasone dipropionate in combination with salmeterol in patients with moderate to severe asthma (abstract). Am J Respir Crit Care Med 1995;151:A276.
80. Ayres JG, Bateman ED, Lundback B, Harris TAJ. High dose fluticasone propionate, 1 mg daily, versus fluticasone propionate, 2 mg daily, or budesonide, 1.6 mg daily, in patients with chronic severe asthma. Eur Respir J 1995;86:579-86.
81. Langdon CG, Capsey LJ. Fluticasone propionate and budesonide in adult asthmatics: a comparison using dry-powder inhaler devices. Br J Clin Res 1994;5:85-99.
82. Ringdal N, Swinburn P, Backman R, Plaschke P, Sips AP, Tell HM, et al. Efficacy and safety of fluticasone propionate 800 mcg/d via the Diskhaler and budesonide 1600 mcg/d via the Turbuhaler (abstract). Am J Respir Crit Care Med 1996;153:A338.
83. Data on file. Schering/Key Pharmaceuticals, Inc. and Food and Drug Administration.
84. Data on file. Schering/Key Pharmaceuticals, Inc. and Food and Drug Administration.
85. Gross G, Wolfe JD, Noonan MJ, Pinnas JL, Boltansky H, Nathan RA, et al. Fluticasone propionate 500 meg/day improves asthma more than triamcinolone acetonide 800 meg/day (abstract). Am J Respir Crit Care Med 1996;153(2):A340.
86. Condemi J, Chervinsky P, Goldstein M, Ayars G, Ford L, Berger W, et al. Fluticasone propionate 500 mcg/day is superior to triamcinolone acetonide 800 mcg/day in controlling asthma (abstract). Am J Respir Crit Care Med 1996;153(2):A801
87. Trautmann M, Ackerman W. Efficacy of fluticasone propionate (0.5 mg daily) and flunisolide (1.0 mg daily) in steroid-naive asthmatics (abstract). Am J Respir Crit Care Med 1995;151(suppl):A275.
88. McCubbin MM, Milavetz G, Grandgeorge S, Weinberger M, Ahrens R, Sargent C, et al. A bioassay for topical and systemic effect of three inhaled corticosteroids. Clin Pharmacol Ther 1995;57:455-60.
89. Cockcroft DW, Murdock KY. Comparative effects of inhaled salbutamol, sodium cromoglycate, and beclomethasone dipropionate on allergen-induced early asthmatic responses, and increased bronchial responsiveness to histamine. J Allergy Clin Immunol 1987;79:734-40.
90. Dahl R, Johansson S-A. Importance of duration of treatment with inhaled budesonide on the immediate and late bronchial reaction. Eur J Respir Dis 1982;63(suppl 122):108-17.
91. Djukanovic R, Wilson JW, Britten KM, Wilson SJ, Walls AF, Roche WR, et al. Effect of an inhaled corticosteroid on airway inflammation and symptoms in asthma. Am Rev Respir Dis 1992;145:669-74.
92. Brown PH, Blundell G, Greening AP, Crompton GK. Do large volume spacer devices reduce the systemic effects of high dose inhaled corticosteroids? Thorax 1990;45:736-9.
93. Selroos O, Halme M. Effect of a volumatic spacer and mouth rinsing on systemic absorption of inhaled corticosteroids from a metered dose inhaler and dry powder inhaler. Thorax 1991;46:891-4.
94. Brown PH, Matusiewicz SP, Shearing C, Tibi L, Greening AP, Crompton GK. Systemic effects of high dose inhaled steroids: comparison of beclomethasone dipropionate and budesonide in healthy subjects. Thorax 1993;48:967-73.
95. Pedersen S, Fuglsang G. Urine cortisol excretion in children treated with high doses of inhaled corticosteroids: a comparison of budesonide and beclomethasone. Eur Respir J 1988;1:433-5.
96. Prahl P. Adrenocortical suppression following treatment with beclomethasone and budesonide. Clin Exp Allergy 1991;21:145-6.
97. Bisgaard H, Nielsen MD, Andersen B, Andersen P, Foged N, Fuglsang G, et al. Adrenal function in children with bronchial asthma treated with beclomethasone dipropionate or budesonide. J Allergy Clin Immunol 1988;81:1088-95.
98. Prahl P, Jensen T, Bjerregaard-Andersen H. Adrenocortical function in children on high-dose steroid aerosol therapy. Allergy 1987;42:541-4.
99. Grahnen A, Eckernas S-A, Brundin RM, Ling-Andersson A. An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers. Br J Clin Pharmacol 1994;38:521-5.
100. Grove A, Allam C, McFarlane LC, McPhate G, Jackson CM, Lipworth BJ. A comparison of the systemic bioactivity of inhaled budesonide and fluticasone propionate in normal subjects. Br J Clin Pharmacol 1994;38:27-32.
101. Clark DJ, Grove A, Cargill RI, Lipworth BJ. Comparative adrenal suppression with inhaled budesonide and fluticasone propionate in adult asthmatic patients. Thorax 1996;51:262-6.
102. Clark DJ, Clark RA, Lipworth BJ. Adrenal suppression with inhaled budesonide and fluticasone propionate given by large volume spacer to asthmatic children. Thorax 1996;51:941-3.
103. Boorsma M, Andersson N, Larsson P, Ullman A. Assessment of the relative potency of inhaled budesonide and fluticasone propionate. Eur Respir J 1996;9:1427-32.
104. Lonnebo A, Grahnen A, Jansson B, Brundin RM, Ling-Andersson A, Eckernas S-A. An assessment of the systemic effects of single and repeated doses of inhaled fluticasone propionate and inhaled budesonide in healthy volunteers. Eur J Clin Pharmacol 1996;49:459-63.
105. Grahnen A, Eckernas S-A, Brundin RM, Ling-Andersson A. An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers. Br J Clin Pharmacol 1994;38:521-5.
106. Corren J, Rachelefsky G, Hochhaus G. A five-way parallel randomized study to compare the safety profile of beclomethasone dipropionate (BDP), budesonide (BUD), flunisolide (FLU), fluticasone propionate (FP), and triamcinolone acetonide (TAA) in healthy male volunteers. Chest 1996;110(suppl):83S.